Related references
Note: Only part of the references are listed.STAT5: From Pathogenesis Mechanism to Therapeutic Approach in Acute Leukemia
Mohammad Shahjahani et al.
LABORATORY MEDICINE (2020)
Strategies to inhibit arsenic trioxide-induced cardiotoxicity in acute promyelocytic leukemia
Habib Haybar et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Michael Hallek et al.
BLOOD (2018)
Chronic Lymphocytic Leukemia: Diagnosis and Treatment
Paolo Strati et al.
MAYO CLINIC PROCEEDINGS (2018)
Preferential use of unmutated immunoglobulin heavy variable region genes in Boxer dogs with chronic lymphocytic leukemia
Emily D. Rout et al.
PLOS ONE (2018)
miR-125a and miR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients
Veronica Balatti et al.
BLOOD (2018)
MiR-223-3p inhibits angiogenesis and promotes resistance to cetuximab in head and neck squamous cell carcinoma
Alexandre Bozec et al.
ONCOTARGET (2017)
PD-1/PD-L1 as a prognostic factor in leukemia
Hadi Rezaeeyan et al.
JOURNAL OF HEMATOPATHOLOGY (2017)
miR-125a-5p inhibits cell proliferation and induces apoptosis in colon cancer via targeting BCL2, BCL2L12 and MCL1
Zhiguo Tong et al.
BIOMEDICINE & PHARMACOTHERAPY (2015)
MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL
Ana E. Rodriguez-Vicente et al.
BMC CANCER (2015)
Molecular pathogenesis of CLL and its evolution
David Rodriguez et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2015)
Role of microRNA in chronic lymphocytic leukemia onset and progression
Veronica Balatti et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
MiR-125a suppresses tumor growth, invasion and metastasis in cervical cancer by targeting STAT3
Zhongyi Fan et al.
ONCOTARGET (2015)
Chronic Lymphocytic Leukemia A Clinical Review
Chadi Nabhan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients
Gian Matteo Rigolin et al.
ONCOTARGET (2014)
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review
Marilena V. Iorio et al.
EMBO MOLECULAR MEDICINE (2012)
MicroRNA-223 expression is uniformly down-regulated in B cell lymphoproliferative disorders and is associated with poor survival in patients with chronic lymphocytic leukemia
Keshu Zhou et al.
LEUKEMIA & LYMPHOMA (2012)
Inducible MicroRNA-223 Down-Regulation Promotes TLR-Triggered IL-6 and IL-1β Production in Macrophages by Targeting STAT3
Qingyun Chen et al.
PLOS ONE (2012)
Two common SNPs in pri-miR-125a alter the mature miRNA expression and associate with recurrent pregnancy loss in a Han-Chinese population
Yi Hu et al.
RNA BIOLOGY (2011)
The DLEU2/miR-15a/16-1 Cluster Controls B Cell Proliferation and Its Deletion Leads to Chronic Lymphocytic Leukemia
Ulf Klein et al.
CANCER CELL (2010)
microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification
Basile Stamatopoulos et al.
BLOOD (2009)
miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities
M. Mraz et al.
LEUKEMIA (2009)
Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis
Holger Schulz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)